Financial Survey: Immune Pharmaceuticals (IMNP) versus Pfizer (PFE)

Immune Pharmaceuticals (NASDAQ: IMNP) and Pfizer (NYSE:PFE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Immune Pharmaceuticals and Pfizer, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immune Pharmaceuticals 0 0 1 0 3.00
Pfizer 1 6 10 0 2.53

Immune Pharmaceuticals presently has a consensus price target of $3.00, suggesting a potential upside of 408.04%. Pfizer has a consensus price target of $38.80, suggesting a potential upside of 5.04%. Given Immune Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Immune Pharmaceuticals is more favorable than Pfizer.

Volatility and Risk

Immune Pharmaceuticals has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Earnings and Valuation

This table compares Immune Pharmaceuticals and Pfizer’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immune Pharmaceuticals N/A N/A -$32.66 million ($3.00) -0.20
Pfizer $52.82 billion 4.17 $7.22 billion $1.63 22.66

Pfizer has higher revenue and earnings than Immune Pharmaceuticals. Immune Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Dividends

Pfizer pays an annual dividend of $1.28 per share and has a dividend yield of 3.5%. Immune Pharmaceuticals does not pay a dividend. Pfizer pays out 78.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has raised its dividend for 8 consecutive years.

Profitability

This table compares Immune Pharmaceuticals and Pfizer’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immune Pharmaceuticals N/A -1,443.76% -117.17%
Pfizer 18.69% 25.41% 8.90%

Institutional & Insider Ownership

1.6% of Immune Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Pfizer shares are owned by institutional investors. 6.7% of Immune Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Pfizer beats Immune Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

About Pfizer

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines, as well as products for consumer healthcare. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply